Genentech Asks A Lot From Avastin Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The Avastin sponsor and FDA each submit their understandings of the central questions to be resolved at the June hearing on CDER's proposal to withdraw the breast cancer indication for bevacizumab.